Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STMC-103H in neonates and infants at risk for allergic disease
NCT05003804Phase 2Completed
- Sponsor
- Siolta Therapeutics
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 3
01
Overview
A Phase 2 trial of STMC-103H in atopic dermatitis (AD), type 1 hypersensitivity, sponsored by Siolta Therapeutics. Started Sep 2021; status: completed.
02
Drugs
STMC-103H
03
Conditions
atopic dermatitis (AD)type 1 hypersensitivity
Beyond the preview
Go deeper on NCT05003804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003804.